Show simple item record

AuthorTurner, S.J.
AuthorSenol, E.
AuthorKara, A.
AuthorAl-Badriyeh, D.
AuthorKong, D.C.M.
AuthorDinleyici, E.C.
Available date2024-04-30T05:47:45Z
Publication Date2013
Publication NameInternational Journal of Antimicrobial Agents
ResourceScopus
Identifierhttp://dx.doi.org/10.1016/j.ijantimicag.2013.04.030
ISSN9248579
URIhttp://hdl.handle.net/10576/54477
AbstractInvasive fungal infections (IFIs) are a major concern within healthcare systems. This pharmacoeconomic study evaluated the use of caspofungin (CAS) versus liposomal amphotericin B (L-AmB) in the empirical treatment of IFIs within the Turkish healthcare system. A decision-analytic model was adopted, utilising data from a randomised, non-inferiority clinical trial and a panel of clinical experts in Turkey. A five-point composite outcome measure was used to evaluate both agents. Sensitivity analyses were performed. In the base-case scenario, CAS was preferred over L-AmB by Turkish Lira (TL) 3961 per patient treated, TL 12 904 per successfully treated patient and TL 3972 per death averted. One-way sensitivity analysis did not change the study outcome. Monte Carlo simulation concluded a 71.0% chance of the outcome favouring CAS. The results were most sensitive to changes in length of stay. This is the first economic evaluation of the empirical treatment of IFIs in Turkey and suggests that CAS is more cost effective than L-AmB.
Languageen
PublisherElsevier
SubjectAntifungal agents
Caspofungin
Economic evaluation
Empirical therapy
Invasive fungal infection
Liposomal amphotericin B
TitlePharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey
TypeArticle
Pagination276-280
Issue Number3
Volume Number42
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record